18 research outputs found
Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic
This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic
Carotenoides en agroalimentación y salud
Los carotenoides son compuestos especiales; si bien es común referirse a ellos como
pigmentos, lo cierto es que son compuestos de gran versatilidad e importancia en la
naturaleza. Más específicamente, son de gran interés en agroalimentación y salud.
Así, por ejemplo, son pigmentos naturales y por lo tanto tienen un importante papel en
la elección de alimentos por parte de los consumidores. Asimismo, algunos de ellos
son precursores de la vitamina A. Sin embargo, que cada vez exista más interés en los
carotenoides en este contexto se debe en gran parte a muchos estudios de distinta
naturaleza que indican que pueden proporcionar beneficios para la salud. Su interés
en alimentación funcional es por lo tanto indudable.
En este libro se refleja la experiencia en carotenoides de un gran número de
profesionales de la región iberoamericana. En conjunto, se ofrece una visión general
de la investigación sobre estos compuestos en agroalimentación y salud. Los autores
son miembros de la red ibercarot (http://carotenoides.us.es), que tiene entre sus
objetivos conformar una red estable y funcional de profesionales que aúnen esfuerzos
en pos de identificar nuevas fuentes de carotenoides de interés nutricional, mejorar su
producción y aumentar el valor de los productos que los contengan.
Me gustaría agradecer a todas y cada una de las personas que han contribuido de
una u otra forma a que este libro sea una realidad. Todos esperamos que sea de
ayuda para personas interesadas en los temas desarrollados. Gracias especialmente
al Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo (Cyted, http://
www.cyted.org/) que, con su apoyo económico a la red ibercarot, ha hecho posible
que varias decenas de equipos interaccionen en torno a temas de interés común para
contribuir al desarrollo a distintos niveles de la región iberoamericana.RED TEMÁTICA IBERCAROT (referencia 112RT445) http://carotenoides.us.es
PROGRAMA IBEROAMERICANO DE CIENCIA Y TECNOLOGIA PARA EL DESARROLLO – CYTEDPeer reviewe
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
<div><p>Background</p><p>Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment.</p><p>Methods</p><p>Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a response or stable disease during at least 3 years. Patients having a progression in the first year of therapy with trastuzumab were used as a control. Genes related with trastuzumab resistance were identified and investigated for network and gene functional interrelation. Models predicting poor response to trastuzumab were constructed and evaluated. Finally, a mutational status analysis of selected genes was performed in HER2 positive breast cancer samples.</p><p>Results</p><p>103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median duration of response was 55 months. The molecular analysis included 35 patients from the group with complete response and 18 patients in a control poor-response group. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival. Gene ontology analysis demonstrated that PI3K pathway was associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most.</p><p>Conclusions</p><p>Trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression after trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy.</p></div
Supervised hierarchical clustering for all samples using 1052 differentially expressed probesets identified using SAM.
<p>Each row represents a probeset and each column a sample. Green bars indicate samples from patients in Long-HER group, red bars indicate samples from short-term responders. There are two samples duplicated, * account for metastasis samples.</p
Signaling pathway annotation enrichment analysis for 858 genes related with trastuzumab resistance.
<p>This analysis was performed using SPEED software. PI3K pathway appeared as the most relevant pathway in relation with trastuzumab resistance.</p
PI3K-mTOR pathway analyses.
<p>A) Supervised hierarchical clustering for all samples using five genes from the PI3K-mTOR pathway that are differentially expressed between Long-HER and short-term responders to trastuzumab samples. B) Distribution of the normalized expression of these genes.</p
Proposed model of trastuzumab resistance in short-term responders due to Akt/mTOR activation and apoptosis inhibition.
<p>Genes in blue are downregulated, genes in orange are upregulated, genes in red favour Akt/mTOR pathway activation and genes in green decrease Akt/mTOR pathway activation. Red signs are new disrupting elements identified. Green arrow indicates the step regulated by trastuzumab.</p